The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound

Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

[search][options]

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Edward M. Messing

University of Rochester School of Medicine

Rochester

NY, USA. Electronic address:

[email]@*.rochester.edu

Name/email consistency: high

[Claim this account]

Affiliations

University of Rochester School of Medicine, Rochester, NY, USA. Electronic address:. 2009 - 2012
Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, USA. 2003 - 2009

References

Re: Preexisting BCG-specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer. Messing, E.M. Eur. Urol. (2012) [Pubmed]
Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al. Messing, E. Eur. Urol. (2009) [Pubmed]
Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease. Messing, E.M., Madeb, R., Feng, C., Stephenson, L., Gilchrist, K.W., Young, T., Gee, J. J. Clin. Oncol. (2009) [Pubmed]
Markers of detection. Messing, E. Urol. Oncol. (2007) [Pubmed]
Long-term outcome of hematuria home screening for bladder cancer in men. Messing, E.M., Madeb, R., Young, T., Gilchrist, K.W., Bram, L., Greenberg, E.B., Wegenke, J.D., Stephenson, L., Gee, J., Feng, C. Cancer (2006) [Pubmed]
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Messing, E.M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P.A., Trump, D. Lancet Oncol. (2006) [Pubmed]
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. Messing, E., Kim, K.M., Sharkey, F., Schultz, M., Parnes, H., Kim, D., Saltzstein, D., Wilding, G. J. Urol. (2006) [Pubmed]
Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. Messing, E.M., Teot, L., Korman, H., Underhill, E., Barker, E., Stork, B., Qian, J., Bostwick, D.G. J. Urol. (2005) [Pubmed]
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. Messing, E.M., Manola, J., Wilding, G., Propert, K., Fleischmann, J., Crawford, E.D., Pontes, J.E., Hahn, R., Trump, D. J. Clin. Oncol. (2003) [Pubmed]
The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Messing, E. Urol. Oncol. (2003) [Pubmed]
Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Messing, E.M., Thompson, I. Urol. Clin. North Am. (2003) [Pubmed]